Mallinckrodt Announces Journal Publication of Economic Evidence for TERLIVAZĀ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS)

– Analysis indicates treatment with TERLIVAZ plus albumin in adults with HRS with rapid reduction in kidney function1 can help improve kidney function with lower HRS treatment-related healthcare utilization costs2 – – Journal manuscript with full data results now published in the December…